Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
about
Atypical hemolytic uremic syndromeThrombotic microangiopathy with targeted cancer agentsCancer-associated thrombotic microangiopathyDrug-induced glomerular disease: direct cellular injury.Chronic VEGF blockade worsens glomerular injury in the remnant kidney modelAntineoplastic agents and thrombotic microangiopathy.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.A phase I study of sunitinib plus bevacizumab in advanced solid tumors.Thrombotic microangiopathies: multimers, metalloprotease, and beyond.Multifaceted hemolytic uremic syndrome in pediatrics.Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Nephrotic Syndrome and Acute Renal Failure Apparently Induced by SunitinibBevacizumab increases risk for severe proteinuria in cancer patients.Anti-VEGF Cancer Therapy in Nephrology PracticeResidual renal function after partial or radical nephrectomy for renal cell carcinoma.Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeysRenal involvement in preeclampsia: similarities to VEGF ablation therapyImprovement in Gemcitabine-Induced Thrombotic Microangiopathy with Rituximab in a Patient with Ovarian Cancer: Mechanistic Considerations.The risk for anemia with targeted therapies for solid tumorsKidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.Vegfa protects the glomerular microvasculature in diabetes.Minimal change disease onset observed after bevacizumab administration.VEGF inhibition, hypertension, and renal toxicityInhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling.New insights into molecular mechanisms of diabetic kidney disease.Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.Safety profile of new anticancer drugs.Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.Inhibition of the VEGF signalling pathway and glomerular disorders.Onco-nephrology: current concepts and future perspectives.At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature.Sunitinib induced nephrotic syndrome and thrombotic microangiopathy.Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA.Adverse events of monoclonal antibodies used for cancer therapy.Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.Sunitinib-Induced Acute Interstitial Nephritis in a Thrombocytopenic Renal Cell Cancer Patient.Pazopanib-induced Endothelial Injury with Podocyte Changes.Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.
P2860
Q21202864-51DD74B9-67FD-4CD0-918E-344789CE0164Q24635904-EC646EF1-925F-4C79-B8D6-127A84C88AF0Q26738984-6253EF62-F34B-4FAB-AA61-F4ECFBC02C87Q27692666-5B6D17D7-56EE-4266-A7AB-018542816C5FQ28728129-8E0C6F85-834F-4DC3-908D-9DC909D867E8Q30251919-A14A6623-3A63-49A2-9448-0D9E6A634CF7Q30417015-DC4A630A-8D07-44B8-A19D-73CD1CBA094BQ33386345-C86CAF11-2CEC-4E8B-80DB-4C053E2EA764Q33389435-F94094EC-876A-4AF6-8221-F2AC8D94A36AQ33405452-0FBDD5D6-3769-4009-8B60-07B2309E21F4Q33418425-E1AC053D-7740-49D4-B4AB-1DC3129DAC60Q33423350-3B4E001E-155B-474A-A116-3FE10DB88FC7Q34038027-94EBCD3F-2EDC-4741-B76D-44ACE69F61A9Q34124173-020D6B90-BE80-4AB9-AA58-CC1E5E7DCA43Q34152125-07622700-C499-4E60-ACDD-8FD08EF966C2Q34179292-06A64196-7012-4C00-B128-E28A4D01A933Q34557530-125B4198-55B0-4139-AC0D-B7C0F5E1FD4CQ34735646-E6A79C7B-B2D5-4FC6-8336-A2B659E14B47Q35901666-9B0F96A5-9869-410E-A5B5-87B8C7EF47DEQ35989994-48139974-F050-4368-BF80-41D4C2CB175CQ36150811-E718448D-6BDD-4EC3-92FF-3F9C7DFBAA83Q36339615-5CC2D146-B443-4EF7-8066-BD28EE7BE95BQ36689167-60566C4F-B4D9-4BCC-A0A5-74882AD640EBQ37103555-C6BB81E3-E9A6-4021-8DAC-34706BD3F749Q37416913-9FC3E5CC-F5CB-4D9F-B54B-412D3D252810Q37598306-5BB82B47-181D-4948-8E23-0A670EC18743Q37598818-1037749C-C5EE-4C33-A5D5-1BFB3C1E138CQ37696502-AB90955A-961E-453B-89A9-50DA80D80580Q38169098-83C4EB0D-8922-471B-8206-A6FD676126D1Q38284055-282F46CB-9AA3-4CE4-A9E1-2AA5F30610BBQ38382457-C1B1086E-D0AA-49BB-B3F6-6B918E12104EQ39309248-BCCEFA50-3F32-4F0D-846D-C4A4B512D3FCQ39712982-B7814AE3-70EB-4FAE-9E04-F733715FC3E9Q40336593-AA471095-260B-4077-B51F-04ED99248F85Q40812370-3976C524-0AA9-4170-BB12-57E7C22AD73EQ41612851-341FD52B-0CB5-4AD6-9DAF-62A8E17CC7D0Q47649385-38723412-A481-459D-B730-DE03F5DD96A9Q47672645-35B8016E-B25D-44BD-9A2D-5176557E9FC6Q53239742-FD2BD2D3-E502-4A9B-8ECA-CA1BC63F9294Q54494865-4FD13571-C173-406D-B9CD-B29FEB9DA81C
P2860
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
@en
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
@nl
type
label
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
@en
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
@nl
prefLabel
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
@en
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
@nl
P2093
P2860
P50
P356
P1476
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
@en
P2093
Bertrand Knebelmann
Caroline Robert
Fadi Fakhouri
Guillaume Bollée
Géraldine Cazajous
Laure-Hélène Noël
Natacha Patey
P2860
P304
P356
10.1093/NDT/GFN657
P407
P577
2008-12-02T00:00:00Z